glp 1 drugs stocks Betting on GLP-1 I'm stuck in the gray
Description
If passed, TROA would: Permanently allow Medicare Part D to cover FDA-approved anti-obesity medications Expand Medicare Part B coverage of intensive behavioral therapy for obesity to include a wider range of providers (not just primary care physicians) However, in April 2025, CMS announced it would not include Medicare Part D coverage of obesity drugs in its rule changes for 2026, stating the proposal was "not appropriate at this time." That decision pushed the issue back to Congress, where the TROA remains under consideration
Additionally, continuous progress in developing oral incretin formulations has enhanced their effectiveness, safety, and overall user adherence
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al
Cardiovascular and Renal Considerations Several GLP-1 receptor agonists (specifically liraglutide, semaglutide, and dulaglutide) have demonstrated cardiovascular benefits in clinical trials
In this case, the affinity would weaken if Glu was replaced with a lactam bridge because the charge would be dispersed
The rise of ozempic face: analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists
